durvalumab

February 21, 2019

First Patient Dosed in Trial of ADCT-402 for Advanced Non-Hodgkin’s Lymphoma

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imfinzi (durvalumab) in multiple types of advanced non-Hodgkin’s lymphoma has dosed the first patient. The study (NCT03685344) is for adults with ... Read more

September 8, 2017September 10, 2017

FDA Places Holds on Imfinzi Trials Following Unexplained Deaths in Keytruda Trials

News

The U.S. Food and Drug Administration (FDA) has placed a partial hold on two clinical trials testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory drug in lymphoma and leukemia patients. ... Read more

December 21, 2015

Last Week’s Top 3 Most Read Posts About Lymphoma

Read the Articles Here: Study in Advanced B Cell Lymphoma Patients Reports Good Results and an Expansion Celgene and Astrazeneca To Initiate Fusion Trial for Durvalumab in Hematologic Disorders, Lymphoma ... Read more

December 14, 2015December 14, 2015

Celgene and Astrazeneca To Initiate Fusion Trial for Durvalumab in Hematologic Disorders, Lymphoma

News

AstraZeneca and Celgene Corporation recently announced they will initiate the FUSION clinical development program for investigational anti-PDL1 immune checkpoint inhibitor durvalumab (MEDI4736) in hematologic disorders, including lymphoma. The announcement was made ... Read more